Naftolin Frederick, Taylor Hugh S, Karas Richard, Brinton Eliot, Newman Isadore, Clarkson Thomas B, Mendelsohn Michael, Lobo Rogerio A, Judelson Debra R, Nachtigall Lila E, Heward Christopher B, Hecht Harvey, Jaff Michael R, Harman S Mitchell
Yale University, Department of Obstetrics, Gynecology and Reproductive Sciences, New Haven, Connecticut 06520-8063, USA.
Fertil Steril. 2004 Jun;81(6):1498-501. doi: 10.1016/j.fertnstert.2004.02.095.
The Women's Health Initiative (WHI) randomized controlled trial failed to show cardioprotection by estrogen plus progestin treatment of postmenopausal women. But by design, the WHI population was 10-fold underpowered to show cardioprotection of women starting hormone treatment during the menopausal transition. Thus, observational studies that showed cardioprotection in such women remain the only applicable clinical guide to this issue. Randomized controlled trials are urgently needed to test cardioprotection in women starting treatment during the menopausal transition.
妇女健康倡议（WHI）随机对照试验未能证明雌激素加孕激素治疗绝经后妇女具有心脏保护作用。但根据设计，WHI研究人群在显示绝经过渡期间开始激素治疗的妇女的心脏保护作用方面的检验效能不足实际所需的十分之一。因此，显示此类妇女具有心脏保护作用的观察性研究仍然是关于这个问题的唯一适用临床指南。迫切需要进行随机对照试验来检验绝经过渡期间开始治疗的妇女是否具有心脏保护作用。
Zotero 插件